First Time Loading...

Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 23.7 USD 0.72%
Updated: Apr 29, 2024
Section:
 

Relative Value

The Relative Value of one EXEL stock under the Base Case scenario is 22.18 USD. Compared to the current market price of 23.7 USD, Exelixis Inc is Overvalued by 6%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EXEL Relative Value
Base Case
22.18 USD
Overvaluation 6%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.9
P/S
P/S
Price to Sales
3.9
vs History
68
vs Industry
70
Median 3Y
3.9
Median 5Y
5.1
Industry
8.1
Forward
3.7
More Details
34.5
P/E
P/E
Price to Earnings
34.5
vs History
38
vs Industry
5
Median 3Y
34.5
Median 5Y
28.8
Industry
26.2
Forward
18.8
More Details
21.5
P/OCF
P/OCF
Price to OCF
21.5
vs History
15
vs Industry
8
Median 3Y
18.7
Median 5Y
17
Industry
22.6
More Details
24.5
P/FCFE
P/FCFE
Price to FCFE
24.5
vs History
17
vs Industry
6
Median 3Y
20.2
Median 5Y
18.5
Industry
21.3
More Details
3.2
P/B
P/B
Price to Book Value
3.2
vs History
44
vs Industry
31
Median 3Y
2.9
Median 5Y
3.1
Industry
2.5
More Details
3.4
EV/S
EV/S
Enterprise Value to Sales
3.4
vs History
61
vs Industry
62
Median 3Y
3.2
Median 5Y
3.9
Industry
7.3
Forward
3.2
More Details
3.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.5
vs History
61
vs Industry
63
Median 3Y
3.3
Median 5Y
4.1
Industry
9.1
More Details
31.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
31.4
vs History
23
vs Industry
4
Median 3Y
28.4
Median 5Y
18.5
Industry
4.4
Forward
12.3
More Details
36.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
36.2
vs History
23
vs Industry
3
Median 3Y
32.7
Median 5Y
19.3
Industry
4.3
Forward
14.9
More Details
18.5
EV/OCF
EV/OCF
Enterprise Value to OCF
18.5
vs History
12
vs Industry
8
Median 3Y
14.5
Median 5Y
14.2
Industry
5.4
More Details
21.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
21.1
vs History
12
vs Industry
6
Median 3Y
16.7
Median 5Y
15.4
Industry
3.2
More Details
3.2
EV/IC
EV/IC
Enterprise Value to IC
3.2
vs History
71
vs Industry
40
Median 3Y
3.3
Median 5Y
4.3
Industry
5
More Details

Multiples Across Competitors

EXEL Competitors Multiples
Exelixis Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Exelixis Inc
NASDAQ:EXEL
7.2B USD 3.9 34.5 31.4 36.2
US
Abbvie Inc
NYSE:ABBV
281.9B USD 5.2 58.5 12.7 19.4
US
Amgen Inc
NASDAQ:AMGN
144.5B USD 5.1 21.5 16.1 24.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 10.4 28.3 22.6 23.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
96.6B USD 7.4 24.4 16.1 17.7
AU
CSL Ltd
ASX:CSL
132.9B AUD 6.1 35.1 21.3 26.4
US
Gilead Sciences Inc
NASDAQ:GILD
81.5B USD 3 14.4 7.9 10.2
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Moderna Inc
NASDAQ:MRNA
41.2B USD 6 -8.7 -9.2 -7.8
US
Biogen Inc
NASDAQ:BIIB
30.3B USD 3.1 26.1 14.2 17.6
IE
Horizon Therapeutics PLC
NASDAQ:HZNP
26.6B USD 7.3 60.8 27.9 47

See Also

Summary
EXEL intrinsic value, competitors valuation, and company profile.
DCF Valuation
EXEL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EXEL stock valuation using valuation multiples.
Wall Street Estimates
EXEL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EXEL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.